Quick Dispatch:
Your dihexa hgf/c-met agonist Dihexa is a synthetic peptide derived from Angiotensin IV, engineered to cross the blood-brain barrier and activate the HGF/c-Met pathway — a primary driver of synaptogenesis and new neural connection growth. Researchers orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your dihexa hgf/c-met agonist Dihexa is a synthetic peptide derived from Angiotensin IV, engineered to cross the blood-brain barrier and activate the HGF/c-Met pathway — a primary driver of synaptogenesis and new neural connection growth. Researchers ships.
Need Help?
Questions about dihexa hgf/c-met agonist Dihexa is a synthetic peptide derived from Angiotensin IV, engineered to cross the blood-brain barrier and activate the HGF/c-Met pathway — a primary driver of synaptogenesis and new neural connection growth. Researchers, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for dihexa hgf/c-met agonist Dihexa is a synthetic peptide derived from Angiotensin IV, engineered to cross the blood-brain barrier and activate the HGF/c-Met pathway — a primary driver of synaptogenesis and new neural connection growth. Researchers in your area.
Small Molecule AngIV-based Analogs to Treat Alzheimers Disease
25.29
The HGF/c-Met signaling axis. After HGF binding to the c-Met receptor
25.32
Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
22.34
Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury
28.56
Dihexa (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects in preclinical models. The often-quoted
22.84
The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
28.61
Activated HGF-c-Met Axis in Head and Neck Cancer
21.71
